Search results
EHA 2024: Odronextamab shows promise in ELM-2 study for follicular lymphoma
Clinical Trials Arena via Yahoo Finance· 4 days agoFollicular lymphoma (FL) is a chronic disease that accounts for about 20% of non-Hodgkin's lymphoma...
U.S. FDA approves Roche's lymphoma therapy
Reuters via Yahoo News· 1 year agoFollicular lymphoma is a slow-growing type of non-Hodgkin lymphoma, a cancer that starts in body's white blood cells called lymphocytes. The disease...
Bristol Myers (BMY) Announces CAR T Cell Therapy Breyanzi Data
Zacks via Yahoo Finance· 1 year agoBristol Myers' (BMY) CAR T cell therapy Breyanzi (lisocabtagene maraleucel) shows deep and durable...
Pharma Stock Roundup: FDA Gives Nod to RHHBY's Lunsumio, Accepts PFE Vaccine BLA
Zacks via Yahoo Finance· 1 year agoThis week, the FDA approved Roche’s RHHBY Lunsumio, a first-in-class bispecific antibody, for...
Toronto influencer Susete Isabel says she initially ignored her stage 4 cancer symptoms: 'It's a bad...
Yahoo Canada Style· 2 months agoCanadian influencer Susete Isabel opened up about cancer symptoms she initially "ignored."...
US FDA approves expanded use of Bristol Myers' cancer cell therapy (May 15)
Reuters via Yahoo News· 1 month agoThe U.S. health regulator on Wednesday approved the expanded use of Bristol Myers Squibb's cancer...
Tattoos Increase Risk of Developing Lymphoma by 21%, New Study Finds
People via Yahoo News· 4 weeks agoA new study revealed that getting a tattoo — regardless of size — increases the risk of developing...
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
Zacks via Yahoo Finance· 2 years agoGilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult...
Tattoos may be risk factor for malignant lymphoma, study finds
Deseret News via Yahoo News· 3 weeks agoA hot air balloon pilot sports a tattoo during launch as part of America's Freedom Festival in...
Roche's (RHHBY) Lunsumio Gets FDA Nod for Follicular Lymphoma
Zacks via Yahoo Finance· 1 year agoRoche RHHBY announced that the FDA approved intravenously-administered Lunsumio (mosunetuzumab) for...